Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Atea Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AVIR
Nasdaq
2834
ateapharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
- Mar 6th, 2026 6:30 am
Atea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ...
- Mar 5th, 2026 10:02 pm
Atea Pharmaceuticals Q4 Earnings Call Highlights
- Mar 5th, 2026 4:47 pm
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Mar 5th, 2026 2:05 pm
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
- Feb 26th, 2026 5:00 am
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
- Feb 24th, 2026 5:00 am
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
- Feb 3rd, 2026 8:20 am
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
- Feb 3rd, 2026 8:06 am
Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks
- Jan 23rd, 2026 11:05 am
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
- Jan 19th, 2026 9:19 am
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference
- Jan 15th, 2026 12:32 pm
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock
- Jan 13th, 2026 11:30 am
Atea Pharmaceuticals to highlight strategic priorities for FY26
- Jan 9th, 2026 5:17 am
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
- Jan 8th, 2026 5:00 am
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Jan 6th, 2026 5:00 am
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
- Dec 22nd, 2025 5:00 am
Nano Dimension And 2 Other Penny Stocks With Promising Potential
- Dec 17th, 2025 11:05 am
We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Rate
- Dec 10th, 2025 5:29 am
ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman
- Dec 2nd, 2025 2:46 pm
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ...
- Nov 19th, 2025 6:02 pm
Scroll